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Summary
Objective: Aim of the study was to assess the efficacy and safety of levetiracetam as
add-on treatment in patients with partial-onset epilepsy in clinical practice.
Methods: In this observational, multi-centre study patients were treated with leve-
tiracetam for 16 weeks. From a starting dose of 1000 mg/day, dose levels were
adjusted at 2-weekly intervals in 1000-mg steps, to amaximum of 3000 mg/day, based
on seizure control and tolerance. Analysis of efficacy was based on reduction in
seizure frequency relative to baseline, 50% and 100% responder rates (for partial
seizures and all seizure types combined) and percentage of patients using levetir-
acetam at the end of the study. Analysis of safety was based on occurrence of adverse
events.
Results: The present analysis concerns the results of patients recruited in Belgium
and The Netherlands. Of the 251 patients included in the study, 86.9% completed 16* Corresponding author. Tel.: +31 40 227 90 22; fax: +31 40 226 56 91.
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weeks of treatment. Reduction in frequency of partial-onset seizures was 62.2%, with
19.3% of the patients becoming seizure free and 56.6% having a reduction in seizure
frequency of 50%. These percentages were more or less the same when calculated
for all seizure types combined. Tolerance of levetiracetam treatment was good, with
most adverse events being only mild to moderate in severity, and only 10.0% of the
adverse events leading to discontinuation from the study. Asthenia, somnolence,
dizziness and headache were the most frequently reported adverse events.
Conclusion: Levetiracetam is effective and safe as add-on treatment for partial-
onset seizures in clinical practice.
# 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Epilepsy is a very common neurological disorder
affecting around 50 million people world-wide.1
Partial epilepsies, related to a focal brain dysfunc-
tion, are the most frequently occurring types,
accounting for approximately 60% of cases.2 Though
treatment with anti-epileptic drugs, either as
monotherapy or as a combination of two or more
compounds, is effective in the majority of patients,
seizure control has been reported to be inadequate
in about 25% of the patients.3
Levetiracetam (Keppra1, UCB Pharma, Belgium)
is a new anti-epileptic compound, which has been
registered in the USA, the EU and several other
countries world-wide as add-on therapy in the treat-
ment of adult epileptic patients with partial-onset
seizures with or without secondary generalization.
Levetiracetam is chemically unrelated to other anti-
epileptic drugs and its exact mechanism of action
also appears to be different.4 The properties con-
sidered likely to be related to the anti-epileptic
activity are: specific binding to the synaptic vesicle
protein 2A (SV2A) in the brain,5 selective inhibition
of high voltage-activated (N-type) calcium chan-
nels,6,7 reduction of Ca2+ release from intraneuronal
stores (ryanodine receptors)8 and reversal of the
inhibition by negative allosteric modulators of
GABA- and glycine-gated currents (zinc, b-carbo-
lines).9
Levetiracetam has a very favourable pharmaco-
kinetic profile10 with rapid and complete absorp-
tion, very low protein binding and elimination
mainly by renal excretion with limited metaboliza-
tion, which results in linear pharmacokinetics and
absence of interactions with concomitantly used
drugs, including other anti-epileptic drugs.10—12
The efficacy of levetiracetam as add-on treat-
ment in partial-onset epilepsies has been shown in a
number of clinical studies. In placebo-controlled
trials in refractory patients13—16 (review published
by Privitera17), levetiracetam was shown to signifi-
cantly reduce seizure frequency, with a substantial
percentage of patients becoming seizure free, and
with high responder rates in the remaining patients.All dose levels in the 1000—3000 mg per day dose
range were superior to placebo, with the extent of
efficacy being dose-related.18 Levetiracetam has
been shown to have a rapid onset of action,19 to
be effective in all partial seizure subtypes (simple
and complex partial seizures and secondary general-
ized seizures),20 and to retain its effectivity during
long-term use.21 Treatment with levetiracetam was
very well tolerated, without major differences in
adverse events between levetiracetam and pla-
cebo,13—16 except for a higher incidence of somno-
lence, asthenia, dizziness and headache. There was
no clear dose—response relationship for adverse
events. Adverse events were generally mild to mod-
erate in severity.
Results from two large Phase IV observational
studies, the KEEPERTM (Keppra1 Epilepsy Evaluation
of the Patient timE to Response) study performed in
the USA22 and the SKATETM (Safety of Keppra1 as
Adjunctive Therapy in Epilepsy) study in the rest of
the world23 (only interim data available) confirm the
efficacy and safety of levetiracetam in clinical prac-
tice rather than in a regulatory randomized clinical
trial setting. The current publication describes the
full results of the SKATETM trial in patients recruited
in Belgium and The Netherlands.Materials and methods
Design
The study was designed as a Phase IV, prospective
open-label, multicentre study on the efficacy and
safety of levetiracetam as add-on therapy in the
treatment of partial-onset seizures in epileptic
patients in clinical practice. Patients were to be
treated for 16 weeks at dose levels between 1000
and 3000 mg/day, to be determined during indivi-
dual titration based on seizure control and toler-
ance. A total of 1548 patients were included by 248
study centres world-wide. The current publication
describes the full results obtained in patients
recruited in Belgium (42 centres) and The Nether-
lands (14 centres). In each study centre the protocol
436 D.A.J.E. Lambrechts et al.was approved by an Independent Ethics Committee.
The study was performed in compliance with the
Declaration of Helsinki (with amendments), current
ICH guidelines for Good Clinical Practice and
national laws and regulations.
Patients
To be eligible for inclusion patients (male and
female) had to be at least 16 years of age, and have
epilepsy with partial-onset seizures (with or without
secondary generalization) that are classifiable
according to the International Classification of Epi-
leptic Seizures.24 Patients were to have at least one
and not more than fourteen partial seizures per
month, calculated as mean seizure frequency over
the 3-month period preceding the selection visit.
They were to use one or two concomitant marketed
anti-epileptic drugs at baseline, to be used for at
least 4 weeks before the first visit at a stable dose
regimen. Benzodiazepines used on a daily basis were
considered as one of the concomitant anti-epileptic
drugs, regardless of the prescribed indication.
Patients were not included if they had experi-
enced pseudoseizures within the last year, or
uncountable seizures (clusters) or a history of con-
vulsive status epilepticus within the last 5 years. The
following medical conditions were also reasons for
exclusion: a history of suicide attempt or current
suicidal ideation or other serious psychiatric disor-
ders requiring or having required hospitalization or
medication within the previous 5 years, presence of
progressive cerebral disease, any other progres-
sively degenerative neurological disease or any cer-
ebral tumours or presence of a terminal illness or
any medical condition that might interfere with the
patient’s study participation (including scheduled
elective surgery), as well as haematological
abnormalities (absolute neutrophil counts <1800/
mm3 and/or platelet count <100,000/mm3), or any
disorder or condition affecting pharmacokinetic
behaviour of drugs (such as severe renal or hepatic
impairment; patients with mild or moderate renal
impairment could be included with appropriate dose
adjustment).
Previous exposure to levetiracetam, presence or
history of allergy to levetiracetam (or related sub-
stances) or to one of components of levetiracetam
tablets, participation in a clinical trial within 12
weeks of the selection visit, use of felbamate with
less than 18 months of exposure, or use of vigabatrin
without the recommended assessment of visual field
were also reasons for exclusion. Pregnant or lactat-
ing women were not to be included, and women of
childbearing potential were to use a reliable and
medically acceptable form of birth control.Treatment
Patients received levetiracetam tablets (Keppra1
500 mg tablets; UCB Pharma, Belgium), to be taken
twice daily. All patients started at 1000 mg/day. If
seizure control was considered to be insufficient
after 2 weeks of treatment, the dose level was
increased to 2000 mg/per day, provided the med-
ication was well tolerated. If after 4 weeks of
treatment seizure control was still insufficient,
but tolerance acceptable, the dose level was
increased to 3000 mg/day. Between Week 4 and
the end of the study the dosage could be modified
at any time (increased or decreased in 1000-mg
steps within the 1000—3000 mg/day dose range), to
a level of optimal balance between seizure control
and tolerance.
In case of mild (creatinine clearance 50—79 ml/
min) or moderate (creatinine clearance 30—49 ml/
min) renal insufficiency the daily dose was to be
adjusted to a dose of 1000—2000 mg/day and 500—
1500 mg/day, respectively.
When treatment with levetiracetam was to be
withdrawn the daily dose should be decreased gra-
dually by 1000 mg every 2 weeks.
To allow proper evaluation of the effects of
levetiracetam concomitant anti-epileptic treat-
ment was to remain unchanged during the study,
and was only allowed to be changed when consid-
ered medically necessary.
Assessments
At the selection visit patients gave informed consent
and their compliance with the entrance criteria was
confirmed. Medical history was obtained, including
history of epilepsy (with aetiology) and history and
current use of antiepileptic medication. Historical
seizure count (number of seizures per seizure type
for the past 3 months) was determined. Patients
were examined physically and neurologically, and a
blood sample was taken for haematological and
biochemical screening.
Study visits were planned after 2, 4, 10 and 16
weeks of treatment.
The number and type of seizures were recorded
by the patients on daily record cards, which were
evaluated at each treatment visit. Seizures were
coded by the investigator using the International
Classification of Epileptic Seizures.24 Any changes in
levetiracetam dose and in concomitant antiepilep-
tic medication were documented. Exposure to the
study medication was determined by counting
unused medication and ensuring that non-returned
medication had indeed been used. Information on
occurrence of adverse events and serious adverse
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Table 1 Disposition of patients and exposure to leve-
tiracetam during study period (ITT population)
Number of subjects screened 251
Intention-to-treat (ITT) population 251
Completers 218 (86.9%)
Number of subjects discontinuing
prematurely
33 (13.1%)
Reasons for early discontinuation
Adverse events 25 (10.0%)
Lack of efficacy 11 (4.4%)
Lost to follow-up 2 (0.8%)
Withdrawal of consent 1 (0.4%)
Other reasons 2 (0.8%)
Duration of exposure (days)
Mean (S.D.) 109.8 (30.2)
Median 113
Range 2—185
Q25—Q75 107—120
Daily dose (mg)
Mean (S.D.) 1690.5 (277.9)
Median 2000
Range 500—4000
Q25—Q75 1000—3000events was obtained through observation by the
investigator, spontaneous reporting by the patient
and active questioning of the patients by the inves-
tigator.
After the 16-week study period patients could
choose to continue with levetiracetam treatment on
a prescription basis. Adverse events monitoring was
then to be continued. If patients discontinued treat-
ment at the end of the study (following the with-
drawal dosing scheme described above) they were
to return for a safety visit 2 weeks following the last
levetiracetam dose. At this safety visit evaluation of
seizures, physical and neurological examination,
documentation of changes in antiepileptic and other
concomitant medication and assessment of adverse
events was performed.
Statistical analysis
Both the efficacy and safety analysis were per-
formed on the Intention-to-Treat (ITT) population,
which was defined as the population of patients
included in the study, who took at least one dose
of study medication.
Efficacy was assessed as the percentage reduc-
tion from baseline in seizure frequency, the 50%
responder rate (i.e., percentage of patients with
a reduction in seizure frequency of more than 50%)
and the 100% responder rate (percentage of patients
becoming free of seizures). All efficacy parameters
were calculated separately for Type I seizures (par-
tial-onset or focal seizures) and for all seizures types
combined (Type I = partial-onset or focal seizures;
Type II = generalized seizures, convulsive or non-
convulsive; and Type III = unclassified epileptic sei-
zures).
The retention rate, defined as the number of
patients taking levetiracetam at the end of the
16-week treatment period divided by the total
number of patients included in the study, was also
used as a measure of efficacy.
Safety analysis focused on the nature, incidence
and severity of adverse events.Results
Study population and extent of exposure
A total of 251 patients were included in the study
and constituted the ITT population (Table 1). 86.9%
of the patients completed all 16-weeks of study
duration. Demographic data and characteristics of
epilepsy of the study population are presented in
Table 2. Mean age of the patients was 39.98 years
(S.D. = 13.12; range = 12.0—75.6 year), with themajority (95.6%) of the patients aged between 16
and 65 years.
Most patients had long established epilepsy (mean
duration = 20.52 years; range = 0.4—55.4 years),
with a mean age at onset of 19.45 years (range =
0.1—72.8 years). At study entry all patients suffered
from partial seizures, with a median seizure fre-
quency of 0.9 seizures per week (Q25—Q75 = 0.5—
1.7) (Table 2). Type 1B (complex partial seizures with
impairment of consciousness) was the most fre-
quently reported seizure type (78% of the patients),
with Type IA seizures (simple partial seizures without
impairment of consciousness) and Type IC (partial
seizures evolving to secondarily generalized seizures)
being reported in 34% and 37% of patients, respec-
tively. Generalized seizures (Type II) occurred in only
7% of the patients (Table 2).
Aetiology of epilepsy was reported to be
‘‘unknown’’ for most patients (39%), followed by
cranial trauma (9.2%) and congenital malformation
(8.4%). Most patients (87.3% of the study popula-
tion) had previously used one or more antiepileptic
drugs, the number of different antiepileptic drugs
in history being (% of the patients in brackets) 1
(21.1%), 2 (15.1%), 3 (15.9%), 4 (10.8%), 5 (13.5%), 6
(4.0%), 7 (3.2%), 8 (2.4%) or 9 (0.8% of the patients).
In accordance with the protocol most patients used
1 (39.4%) or 2 (57.0%) antiepileptic drugs at study
entry, with carbamazepine, lamotrigine and val-
proic acid being the most frequently used com-
pounds (Table 3).
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Table 2 Demographic data and other patient char-
acteristics at baseline (ITT population)
Parameter
Age (year)
Mean (S.D.) 39.98 (13.12)
Range 12.0—75.6
Age distribution (N, %)
<16 years 2 (0.8%)
16—65 years 240 (95.6%)
65 years 9 (3.6%)
Gender (N, %)
Female 145 (57.8%)
Male 106 (42.2%)
Duration of epilepsya (year)
Mean (S.D.) 20.52 (13.82)
Range 0.4—55.4
Age at onseta (year)
Mean (S.D.) 19.45 (15.05)
Range 0.1—72.8
History of withdrawal
seizures (N, %)
18 (7.2%)
History of status
epilepticus (N, %)
12 (4.8%)
Aetiology of epilepsyb (N;%)
Brain surgery 7 (2.8%)
Cerebral infection 17 (6.8%)
Cerebral neoplasm 11 (4.4%)
Cerebrovascular accident 11 (4.4%)
Congenital malformation 21 (8.4%)
Cranial trauma 23 (9.2%)
Genetic origin 11 (4.4%)
Perinatal/birth events 16 (6.4%)
Primary degenerative
lesion
3 (1.2%)
Other 36 (14.3%)
Unknown 98 (39.0%)
Missing 1 (0.4%)
Seizure frequency (N)
median (Q25—Q75)
Types I + II + III (N = 250) 1.0 (0.5—1.8)
Type I Partial (focal
seizures)
(N = 250) 0.9 (0.5—1.7)
Type IA Simple partial
seizures
(N = 86) 0.3 (0.0—0.9)
Type IB Complex
partial seizures
(N = 196) 0.9 (0.5—1.6)
Type IC Partial seizures
evolving to secondarily
generalised seizures
(N = 94) 0.2 (0.1—0.5)
Type II Generalized
seizures (convulsive or
non-convulsive)
(N = 17) 0.2 (0.0—0.3)
Type III Unclassified
epileptic seizures
(N = 10) 0.0 (0.0—0.1)
a n = 247.
b Patients may fall into more than one category.
Table 3 Concomitant use of antiepileptic drugs dur-
ing the study (ITT population)
Parameter N %
Number of antiepileptic drugs (at study entry)
0 1 0.4
1 99 39.4
2 143 57.0
3 8 3.2
Number of antiepileptic drugs (at the end of individual
titration)
0 3 1.2
1 110 43.8
2 131 52.2
3 7 2.8
Antiepileptic drugs used by more than 5% of the
patients (over the entire study)
Carbamazepine 133 53.0
Lamotrigine 67 26.7
Valproic acid 45 17.9
Topiramate 22 8.8
Valproate sodium (slow release) 21 8.4
Gabapentin 18 7.2
Phenobarbital 17 6.8
Clonazepam 16 6.4
Oxcarbazepine 15 6.0
Phenytoin 15 6.0
Clobazam 14 5.6Mean duration of exposure was 109.8 days
(S.D. = 30.2), with a mean daily dose of 1690.5 mg
(S.D. = 277.9) (Table 1). There were no marked
differences in exposure between men and women
or between the different age categories.
Efficacy
Levetiracetam, when used as add-on treatment in
patients on stable anti-epileptic medication,
reduced seizure frequency (number of seizures
per week) of partial seizures (Type I) by 62.2%
and of all seizure types combined (Types I + II + III)
by 61.7% (Table 4). A substantial percentage of
patients became completely seizure-free (19.3%
for partial seizures and 18.5% for all seizure types
combined) (Fig. 1a and b). The 50%-responder rate
was 56.6% for both partial seizures and all seizure
types combined. The percentages calculated for
partial seizures only and for all seizure types com-
bined do not differ substantially, because of the low
number of patients with Type II and Type III seizures
at baseline (7% and 4% of the population, respec-
tively; Table 2).
The efficacy of levetiracetam was reflected in a
retention rate of 86.9%, with only 4.4% of the sub-
jects indicating discontinuation because of lack of
efficacy (Table 1).
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Table 4 Effects of treatment on seizure frequency: percentage reduction from baseline over the treatment period
(ITT population)a
Seizure type Seizure frequency at baseline
(number of seizures/week)
Reduction from baseline (%)
N Median Q25—Q75 N Median (%) Q25—Q75 (%)
Partial (Type I) 250 0.9 0.5—1.7 246 62.2 8.4—89.3
Total (Types I + II + III) 250 1.0 0.5—1.8 248 61.7 4.6—88.3
a Patients withdrawing from the study are included up to their last visit.Safety
Though 65.3% of the study population experienced
at least one adverse event, with 55.4% of the
adverse events considered to be related to treat-
ment, in only 10.0% of the patients the adverse
events led to premature discontinuation from the
study and in another 10.4% to dose change or tem-
porary drug discontinuation (Table 5). Asthenia,
convulsion, and somnolence were the most fre-
quently reported adverse events responsible for
premature discontinuation from the study. AllFigure 1 (a) Effect of treatment on partial seizures (Type
I): percentage of patients with a>50% or 100% reduction in
seizure frequency. (b) Effect of treatment on total seizure
frequency (Types I + II + III): percentage of patients with a
>50% or 100% reduction in seizure frequency.adverse events were in general of mild or moderate
severity, with only 8.0% of the patients reporting
adverse events of severe intensity (some patients
reported more than one adverse event of severe
intensity). The most frequently reported adverse
events (>5% of the patients) were related to the
nervous system (somnolence, dizziness, depres-
sion), or were general in nature (asthenia, head-
ache) (Table 6). Only one patient reported a serious
adverse event (convulsion) that was considered to
be related to levetiracetam treatment and led to
discontinuation from the study.Discussion
Patients in clinical practice are more diverse than
patients included in randomized controlled clinical
trials. Controlled clinical trials usually have strict
entrance criteria with respect to age, body weight/
height (BMI), severity of epilepsy, usage of conco-
mitant anti-epileptic medication and comorbidity.
The study population in the observational SKATETMTable 5 Adverse events (ITT population)
N %
Number of patients with adverse
eventsa
Total 164 65.3
Treatment-relatedb 139 55.4
Leading to discontinuation 25 10.0
Leading to dose change or
temporary drug discontinuation
26 10.4
Severe intensityc 20 8.0
Number of patients with serious
adverse events
Total 7 2.8
Treatment-relatedb 1 0.4
Leading to discontinuation 1 0.4
a Some patients reported more than one adverse event.
b Described by the investigator as possibly or probably
related to study medication; adverse events with unknown
relationship are also considered as related to treatment.
c Adverse events with a severe or unknown intensity.
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Table 6 Adverse events occurring in more than 5% of the patients (n = 251)
Adverse event Total Related Not related Mild Moderate Severe
General
Asthenia N 63 60 3 36 26 1
% 25.1 23.9 1.2 14.3 10.4 0.4
Headache N 34 22 12 25 7 2
% 13.5 8.8 4.8 10.0 2.8 0.8
Nervous system
Somnolence N 46 45 1 26 15 5
% 18.3 17.9 0.4 10.4 6.0 2.0
Dizziness N 39 34 5 25 12 2
% 15.5 13.5 2.0 10.0 4.8 0.8
Depression N 13 11 2 6 4 3
% 5.2 4.4 0.8 2.4 1.6 1.2study more closely reflects the patients seen in daily
clinical practice.
While to date only interim results of the European
Skate trial have been published, the current pub-
lication describes the full results of patients
included in the SKATETM trial in Belgium and The
Netherlands. Pooled data of patients from all parti-
cipating countries are currently being analysed.
Analysis of the results of the current study popu-
lation showed that levetiracetam was effective in
the treatment of epilepsy when added to a stable
regimen of one or two other anti-epileptic drugs.
Frequency of partial seizures and of all seizure types
combined was reduced by more than 60%. Seizure
freedom, which is the ultimate goal of treatment,
was obtained in 18—19% of the study population.
More than half of the patients were 50% responders
(i.e., reported a reduction in seizure frequency of
more than 50%).
These results from the subpopulation in Belgium
and The Netherlands do not differ substantially from
the interim results of 731 patients recruited in all
participating countries reported by Steinhoff
et al.23 where 17.2% of the patients became sei-
zure-free, and 49% of patients showed a more than
50% reduction in seizures.
The same level of efficacy was reported in the US
KEEPERTM trial which had a somewhat different
design and included over 1000 patients in a clinical
setting.22 Freedom of seizures was reported in 20%
of the patients included in this study, whereas 57.9%
achieved a reduction in partial seizures of more than
50%.
The efficacy in the observational studies appears
to be higher than that in the placebo-controlled
phase III studies. In the analysis of the pooled data
of the three pivotal placebo-controlled trials efficacy
was shown to be dose-related, with seizure freedom
in 8.6% and a more than 50% reduction in seizures in
41% of the patients receiving 3000 mg/day.18This observed difference in level of efficacy may
be related to differences in patient population and
study design. Though there were no major differ-
ences in demographic and baseline epilepsy char-
acteristics (age of onset, duration of epilepsy),
median baseline seizure frequency was higher in
the Phase III trial population (about 9 per month
in the Phase III studies versus 3—4 per month in the
observational studies). It can also not be excluded
that the population included in the Phase III trials
was more refractory to anti-epileptic treatment.
Perhaps the milder disease type in the clinical prac-
tice resulted in a larger reduction in seizure fre-
quency.
The difference between the open design of the
observational studies and the double-blind charac-
ter of the Phase III trials is also likely to contribute to
the observed higher efficacy, since an open design
will correct less for a possible placebo effect.
Though the way the dose level is selected differs
between the studies (randomization to a fixed dose
level in the Phase III studies versus individual selec-
tion of the dose level for each patient in the obser-
vational studies) this can not explain the observed
difference in level of efficacy. Efficacy in the SKA-
TETM and KEEPERTM trials is calculated and reported
as the average efficacy over the entire 1000—
3000 mg dose range, and would therefore be
expected to be lower, and not higher, than the
efficacy in the 3000 mg dose group in the Phase III
trials, given the established dose—response rela-
tionship for efficacy.18
Treatment with levetiracetam was generally well
tolerated in the study population presented here,
but the percentage of patients reporting adverse
events was slightly higher than that reported in
placebo-controlled studies (65.3% versus 46.4%25).
The percentage discontinuing from the study or
having a dose reduction because of adverse events
was also slightly higher (20.4% in this study versus
Efficacy and safety of levetiracetam in clinical practice 44115% in the placebo-controlled trials26). These dif-
ferences may be due to differences in the study
population (e.g., higher comorbidity), but since no
data on this subject are available, this cannot be
substantiated.
The adverse event profile was similar to that
observed in the placebo-controlled trials and the
KEEPERTM trial,22 with asthenia, somnolence, dizzi-
ness and headache being the most frequently
reported adverse events.26 Adverse events were
mainly mild to moderate in severity. The incidence
of behavioural adverse events (such as hostility,
emotional lability, agitation, anxiety and nervous-
ness) and adverse events related to cognitive dis-
turbances (amnesia, confusion and abnormal
thinking) was low, which is in line with previous
clinical studies.27,28
In conclusion, the results of the SKATETM study
obtained in the study centres in Belgium and The
Netherlands show that levetiracetam is effective
and safe as add-on treatment for partial-onset sei-
zures in a clinical setting. In line with other obser-
vational studies on the effects of levetiracetam, the
therapeutic effect in daily clinical practice appears
to be even more pronounced than in controlled
Phase III trials.Acknowledgements
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